XLRN
Acceleron Pharma
XLRN
XLRN
Delisted
XLRN was delisted on the 19th of November, 2021.
162 hedge funds and large institutions have $1.93B invested in Acceleron Pharma in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 53 increasing their positions, 54 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
25% less capital invested
Capital invested by funds: $2.56B → $1.93B (-$632M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Holders
162
Holding in Top 10
6
Calls
$27.2M
Puts
$3.66M
Top Buyers
| 1 | +$31.9M | |
| 2 | +$11.7M | |
| 3 | +$11.3M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.1M |
| 5 |
Bank of New York Mellon
New York
|
+$10.9M |
Top Sellers
| 1 | -$46.6M | |
| 2 | -$27.5M | |
| 3 | -$10M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.12M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$9.01M |